問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Cardiovascular Diseases

Division of General Internal Medicine

National Taiwan University Hospital Yunlin Branch  (在職)

Division of Cardiovascular Diseases

更新時間：2025-12-16

王宗道Wang, Tzung-Dau
  • Principal Investigator
  • Clinical Trial Experience (year) -24 years -4 個月

Recruiting Trial

27Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

王宗道

List

58Cases

2020-06-11 - 2022-11-02

Others

-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
2Sites

Recruiting2Sites

2021-04-20 - 2024-07-02

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
7Sites

Recruiting7Sites

2022-06-01 - 2024-12-31

Phase III

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting4Sites

Recruiting8Sites

2026-06-01 - 2030-06-30

Phase III

Not yet recruiting
A Phase III, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Study to Evaluate the Effect of Elecoglipron in Reducing Cardiovascular Outcomes in Participants with HFpEF and HFmrEF (Elevate-HF)

  • Condition/Disease

    Sacroiliac Joint Pain

  • Test Drug

    Dapagliflozin Elecoglipron

Participate Sites
14Sites

Recruiting14Sites

2023-03-10 - 2024-11-14

Phase II

Completed
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Not yet recruiting4Sites

2024-03-01 - 2027-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
20Sites

Not yet recruiting11Sites

Recruiting8Sites

2026-01-01 - 2031-09-18

Phase III

Active
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants with Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)

  • Condition/Disease

    Atherosclerosis Cardiovascular Disease Chronic Kidney Disease

  • Test Drug

    Orforglipron (LY3502970) Placebo

Participate Sites
15Sites

Not yet recruiting1Sites

2024-05-01 - 2029-12-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
10Sites

Recruiting10Sites

2024-07-30 - 2028-09-30

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
12Sites

Not yet recruiting8Sites

Recruiting4Sites

2025-07-01 - 2028-05-31

Phase III

Active
-

  • Condition/Disease

    -

  • Test Drug

    -

Participate Sites
5Sites

Recruiting5Sites

1 2 3 4 5 6
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB